A groundbreaking initiative at Princess Margaret Cancer Centre in Ontario aims to screen up to 100,000 individuals over the next five years for genetic conditions linked to hereditary cancers and high cholesterol-related heart disease risks. This large-scale population genomics study in Canada will equip participants and their healthcare providers with valuable screening outcomes to make informed decisions that could potentially delay, mitigate, or prevent cancer and cardiovascular issues. Simultaneously, researchers at the hospital will analyze the comprehensive dataset generated from the screening results in conjunction with patient information to focus on addressing individuals with heightened health vulnerabilities.
The initial phase of the project will focus on cancer patients at the hospital who may harbor genetic predispositions that could impact their treatment regimen or monitoring protocols, according to Dr. Raymond Kim, the medical director of cancer early detection at Princess Margaret. Understanding the genetic profile of these patients is crucial for assessing potential risks for other forms of cancer, stated Kim. Genetic insights can alert healthcare professionals about specific risks and influence the course of treatment. For instance, individuals with BRCA mutations are advised to commence breast monitoring at an early age, while those with Lynch syndrome, associated with various cancers including colorectal, may necessitate colonscopies for proactive management.
One such individual, Leslie Born, a participant in a prior research endeavor at the hospital, received a BRCA2 genetic mutation diagnosis following surgery and biopsy results for advanced ovarian cancer. Despite lacking a significant family history of cancer, Born was screened for various cancer-associated mutations, revealing the unexpected genetic anomaly. This mutation elevates the susceptibility to several cancers, prompting Born to undergo annual breast MRI and mammogram screenings for proactive surveillance based on the genomic insights provided.
Expanding the scope of genetic testing is imperative, particularly as modern family structures have dwindled compared to previous generations, potentially overlooking high-risk individuals within families, highlighted Laura Palma, a certified genetic counselor at McGill University Health Centre in Montreal. Emphasizing the importance of broader access to genetic testing, Palma underscored the need to witness the outcomes of this project and the subsequent actions taken by participants, such as modifying lifestyle habits in response to the genetic revelations.
While the genomic testing and ensuing care are associated with costs, the immediate cost-effectiveness of the project remains unclear, indicating the necessity for comprehensive studies in Canada to evaluate the feasibility and cost-benefit implications for taxpayers, as per Palma. Jenna Scott, co-director of the genetic counseling master’s program at the University of British Columbia, lauded the project’s advancements, noting the affordability and simplicity of genomic testing methods, including the utilization of mouthwash for DNA collection. However, concerns persist regarding the project’s scalability and its alignment with diverse cultural requirements.
The research team intends to disseminate the study findings to participants and leverage the amassed data to ascertain the efficacy of widespread screening initiatives and their relevance to different demographic segments. Dr. Kim envisions extending the enrollment beyond Toronto’s University Health Network to include referrals from family physicians, encompassing family members of patients with familial hypercholesterolemia for tailored counseling, surveillance, and treatments. Helix, a biotechnology company based in California, is collaborating on this transformative project, with stringent privacy safeguards in place overseen by the hospital’s research ethics board.